Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load

被引：0
|
作者：
Baijun Li
Zhaozhe Liu
Xing Liu
Dongchun Liu
Mingyu Duan
Ye Gu
Qiong Liu
Qiang Ma
Yushi Wei
Yan Wang
机构：
[1] The Sixth People’s Hospital of Shenyang,Cadre’s Ward
[2] General Hospital of Northern Theater Command,Oncology Department
[3] The Sixth People’s Hospital of Shenyang,Science and Education Department
[4] Shenyang Pharmaceutical University,School of Traditional Chinese Materia Medica
[5] Shenyang Beichuang Laboratory Co. Ltd,Clinical Chemistry Laboratory
[6] The Sixth People’s Hospital of Shenyang,Gastroenterology Departmentepartment
[7] Liaoning University of Traditional Chinese Medicine,undefined
来源：
Hepatology International | 2021年 / 15卷
关键词：
Tenofovir disoproxil fumarate; Tenofovir alafenamide fumarate; HBV vertical transmission; Pregnant women; Perinatal period; Drug safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1103 / 1108
页数：5
相关论文
共 50 条
  • [41] Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate
    Liang, Lilian Yan
    Yip, Terry Cheuk-Fung
    Lai, Jimmy Che-To
    Lam, Amy Shuk-Man
    Tse, Yee-Kit
    Hui, Vicki Wing-Ki
    Chan, Henry Lik-Yuen
    Wong, Vincent Wai-Sun
    Wong, Grace Lai-Hung
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (09) : 4440 - 4448
  • [42] Renal safety of tenofovir disoproxil fumarate
    Sax, Paul E.
    Gallant, Joel E.
    Klotman, Paul E.
    AIDS READER, 2007, 17 (02): : 90 - +
  • [43] Efficacy and safety of telbivudine and tenofovir disoproxil fumarate in preventing hepatitis B vertical transmission: A real-life practice
    Liu, Jinfeng
    Wang, Jing
    Yan, Taotao
    Du, Dan
    Qi, Caijing
    Cao, Furong
    Yao, Naijuan
    Yang, Yuan
    He, Yingli
    Tian, Zhen
    Ren, Danfeng
    Zhu, Li
    Chen, Tianyan
    Zhao, Yingren
    JOURNAL OF VIRAL HEPATITIS, 2019, 26 (10) : 1170 - 1177
  • [44] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) AT 96 WEEKS IN CHRONIC HBV (CHB) PATIENTS WITH RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE (TDF)
    Chan, Henry Lik-Yuen
    Buti, Maria
    Flisiak, Robert
    Ryder, Stephen
    Streinu-Cercel, Adrian
    Flaherty, John F.
    Gaggar, Anuj
    Mo, Shuyuan
    Subramanian, G. Mani
    Zoulim, Fabrian
    Andreone, Pietro
    Marcellin, Patrick
    GUT, 2018, 67 : A97 - A97
  • [45] Efficacy and Safety of Tenofovir Alafenamide (TAF) at 96 Weeks in Chronic HBV (CHB) Patients with Risk Factors for Use of Tenofovir Disoproxil Fumarate (TDF)
    Buti, Maria
    Stepanova, Tatjana
    Celen, Mustafa K.
    Flisiak, Robert
    Ryder, Stephen D.
    Streinu-Cercel, Adrian
    Gurel, Selim
    Flaherty, John F.
    Gaggar, Anuj
    Suri, Vithika
    Mo, Shuyuan
    Subramanian, Mani
    Nurmukhametova, Elena
    Zoulim, Fabien
    Andreone, Pietro
    Marcellin, Patrick
    HEPATOLOGY, 2017, 66 : 488A - 488A
  • [46] Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naive patients with chronic hepatitis B
    Lim, Jihye
    Choi, Won-Mook
    Shim, Ju Hyun
    Lee, Danbi
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    Choi, Jonggi
    JOURNAL OF HEPATOLOGY, 2022, 77 : S842 - S842
  • [47] Atherosclerotic CVD risk profile of tenofovir alafenamide versus tenofovir disoproxil fumarate
    Huhn, G.
    Shamblaw, D.
    Baril, J. G.
    Baker, D.
    Ward, D.
    Guo, S.
    Haubrich, R.
    Nguyen-Cleary, T.
    McCallister, S.
    Das, M.
    ANTIVIRAL THERAPY, 2016, 21 : A45 - A45
  • [48] Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older
    Stellbrink, H-J
    Post, F. A.
    Podzamczer, D.
    Arribas, J.
    Cua, E.
    Molina, J-M
    Orkin, C.
    Rockstroh, J. K.
    Carter, C.
    Liu, Y-P
    Zhong, L.
    Das, M.
    Temme, L.
    Waters, L.
    HIV MEDICINE, 2019, 20 : 138 - 138
  • [49] Establishing the Mechanisms of Tenofovir Disoproxil Fumarate (TDF) and Tenofovir Alafenamide (TAF) in Osteogenesis
    Lazcano, Itzel
    Patel, Niyati
    Finerty, Declan
    Ross, Ryan
    JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 : 355 - 355
  • [50] Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2
    Cusato, Jessica
    Calcagno, Andrea
    De Nicolo, Amedeo
    Mogyorosi, Karoly
    D'Avolio, Antonio
    Di Perri, Giovanni
    Bonora, Stefano
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2019, 94 (02) : 202 - 204
12345